https://www.bioworld.com/rss en-us http://www.bioworld.com/articles/730787 Tue, 28 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/730787-sun-pharma-to-acquire-merck-spinoff-organon-for-1175b Three red darts on target http://www.bioworld.com/articles/730786 Tue, 28 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/730786-akeso-sets-durability-bar-as-immuno-oncology-20-race-heats-up Pancreas anatomy illustration http://www.bioworld.com/articles/730785 Tue, 28 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/730785-ribo-diagens-tally-2-hong-kong-biotech-medtech-ipos-in-q1-2026 Hong Kong stock market illustration http://www.bioworld.com/articles/730784 Tue, 28 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/730784-china-partnerships-lead-biopharma-deal-surge-in-q1-2026 Chart of arrows pointing upward http://www.bioworld.com/articles/730783 Tue, 28 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/730783-cochlears-39-stock-plunge-resets-defensive-growth-narrative Cochlear Nucleus system Nucleus Nexa cochlear implant system. Credit: Cochlear Ltd. BioWorld tracked 209 clinical trial readouts across phases I through III in March 2026, up from 152 in February and 144 in January. Among late-stage programs, 26 phase III trials reported positive results, two produced mixed results, and three failed to meet key endpoints. By phase, March updates included 62 from phase I, 74 from phase II and 73 phase III.]]> http://www.bioworld.com/articles/730782 Tue, 28 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/730782-xenon-spikes-theravance-sinks-after-phase-iii-readouts-in-march Health professional pointing stethoscope at Clinical Trial words, icons http://www.bioworld.com/articles/730671 Tue, 28 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/730671-pilatus-plt-012-takes-immunometabolic-approach-to-reprogram-tme Illustration of monoclonal antibody treatment for cancer http://www.bioworld.com/articles/730670 Tue, 28 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/730670-chinese-biotechs-gain-leverage-as-partners-in-dealmaking Chinabio 2026 partnering China’s evolution in the dealmaking arena was the hot topic of discussion on the first day of the Chinabio Partnering Forum. http://www.bioworld.com/articles/730632 Tue, 28 Apr 2026 08:00:00 -0400 https://www.bioworld.com/articles/730632-regulatory-actions-for-april-28-2026 http://www.bioworld.com/articles/730631 Tue, 28 Apr 2026 08:00:00 -0400 https://www.bioworld.com/articles/730631-other-news-to-note-for-april-28-2026 http://www.bioworld.com/articles/730630 Tue, 28 Apr 2026 08:00:00 -0400 https://www.bioworld.com/articles/730630-in-the-clinic-for-april-28-2026 http://www.bioworld.com/articles/730628 Tue, 28 Apr 2026 08:00:00 -0400 https://www.bioworld.com/articles/730628-appointments-and-advancements-for-april-28-2026 http://www.bioworld.com/articles/435994 Tue, 28 Apr 2026 01:00:00 -0400 https://www.bioworld.com/articles/435994-news-in-brief http://www.bioworld.com/articles/730581 Tue, 21 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/730581-delta-fly-eyes-nda-path-despite-aml-phase-iii-miss Acute myeloid leukemia illustration http://www.bioworld.com/articles/730580 Tue, 21 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/730580-fda-grants-priority-review-to-merck-daiichis-b7-h3-cancer-adc Lung cancer illustration http://www.bioworld.com/articles/730579 Tue, 21 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/730579-xuanzhu-shares-dip-despite-phase-iii-alk-inhibitor-data Lung cancer illustration http://www.bioworld.com/articles/730578 Tue, 21 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/730578-mabwell-turns-to-hong-kong-to-fund-adc-ambitions HKEX exterior Credit: Lewis Tse Pui Lung - stock.adobe.com http://www.bioworld.com/articles/730577 Tue, 21 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/730577-pricing-standoff-leaves-australian-patients-in-limbo White tablet imprinted with dollar sign BioWorld. Remedy is taking a secretome-based approach to treat lung disorders, having moved its lead asset, RC-0315, into a first-in-human clinical trial for idiopathic pulmonary fibrosis (IPF) in January. ]]> http://www.bioworld.com/articles/730576 Tue, 21 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/730576-remedy-pushes-cell-free-secretome-therapy-for-ipf-into-phase-i Ayele Dilion Mashiah, CEO, Remedy Ayelet Dilion Mashiah, CEO, Remedy Cell Ltd. http://www.bioworld.com/articles/730574 Tue, 21 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/730574-daiichi-to-divest-consumer-health-unit-to-suntory-for-15b Two arrows in opposite directions http://www.bioworld.com/articles/730573 Tue, 21 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/730573-med-tech-financings-steady-at-88b-in-q1-despite-volume-drop Layered charts http://www.bioworld.com/articles/730486 Tue, 21 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/730486-early-data-position-junshi-in-next-gen-immuno-oncology-race Illustration of cancer cells and immunotherapy treatment http://www.bioworld.com/articles/730485 Tue, 21 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/730485-biogen-amasses-full-felzartamab-rights-with-850m-tj-deal Global handshake silhouette Nature Communications. The study challenges a longstanding assumption in optical engineering that highly ordered, periodic structures are required to precisely control light.]]> http://www.bioworld.com/articles/730575 Tue, 21 Apr 2026 09:00:00 -0400 https://www.bioworld.com/articles/730575-kaleidoscope-like-engineered-disorder-expands-imaging-potential Photo of kaleidoscope pattern http://www.bioworld.com/articles/730534 Tue, 21 Apr 2026 08:00:00 -0400 https://www.bioworld.com/articles/730534-regulatory-actions-for-april-21-2026 http://www.bioworld.com/articles/730533 Tue, 21 Apr 2026 08:00:00 -0400 https://www.bioworld.com/articles/730533-other-news-to-note-for-april-21-2026 http://www.bioworld.com/articles/730532 Tue, 21 Apr 2026 08:00:00 -0400 https://www.bioworld.com/articles/730532-in-the-clinic-for-april-21-2026 http://www.bioworld.com/articles/730531 Tue, 21 Apr 2026 08:00:00 -0400 https://www.bioworld.com/articles/730531-financings-for-april-21-2026 http://www.bioworld.com/articles/730530 Tue, 21 Apr 2026 08:00:00 -0400 https://www.bioworld.com/articles/730530-appointments-and-advancements-for-april-21-2026 http://www.bioworld.com/articles/730423 Tue, 14 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/730423-oricell-raises-110m-in-pre-ipo-round-to-advance-solid-tumor-car-ts Liver anatomy on medical background